Published in Lung Cancer on November 30, 2011
The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20
Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res (2013) 1.12
Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo. Neoplasia (2015) 0.87
Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature (2017) 0.87
Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib. Cancer Sci (2015) 0.81
Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Invest New Drugs (2013) 0.81
Comprehensive suppression of all apoptosis-induced proliferation pathways as a proposed approach to colorectal cancer prevention and therapy. PLoS One (2014) 0.80
Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines. PLoS One (2013) 0.80
miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs. Nucleic Acids Res (2014) 0.80
Mutation of cysteine 46 in IKK-beta increases inflammatory responses. Oncotarget (2015) 0.79
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene (2015) 0.79
Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR. Oncotarget (2015) 0.78
T790M is associated with a favorable prognosis in Japanese patients treated with an EGFR-TKI. Lung Cancer (2012) 0.78
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. J Thorac Oncol (2016) 0.75
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res (2004) 18.86
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res (2005) 10.46
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med (2010) 8.59
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res (2004) 7.76
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol (2005) 5.63
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med (2012) 4.90
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res (2006) 4.62
Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci (2005) 4.55
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res (2008) 4.30
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci (2007) 3.52
Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. J Thorac Oncol (2012) 3.10
A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol (2011) 2.78
Diagnostic utility of EUS-guided FNA in patients with gastric submucosal tumors. Gastrointest Endosc (2010) 2.67
Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res (2007) 2.59
Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One (2008) 2.52
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J (2009) 2.42
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc (2011) 2.39
Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol (2006) 2.37
Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol (2011) 2.34
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol (2009) 2.33
Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology (2006) 2.33
TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol (2002) 2.32
Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res (2008) 2.30
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
Colorectal cancer screening with odour material by canine scent detection. Gut (2011) 2.23
Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. Ann Thorac Surg (2006) 2.21
Obstructing spontaneous major shunt vessels is mandatory to keep adequate portal inflow in living-donor liver transplantation. Transplantation (2013) 2.14
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol (2011) 2.07
Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol (2003) 2.06
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res (2010) 2.05
Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. J Thorac Oncol (2014) 2.04
Bile duct adenoma and von Meyenburg complex-like duct arising in hepatitis and cirrhosis: pathogenesis and histological characteristics. Pathol Int (2014) 2.01
Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res (2005) 1.99
Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med (2012) 1.98
An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol (2014) 1.97
Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol (2004) 1.89
Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res (2006) 1.89
Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res (2008) 1.88
Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology (2010) 1.86
Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int (2010) 1.86
Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol (2012) 1.85
Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol (2009) 1.85
Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol (2012) 1.84
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol (2009) 1.81
Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer (2011) 1.81
Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol (2009) 1.78
Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets (2008) 1.75
How long should small lung lesions of ground-glass opacity be followed? J Thorac Oncol (2013) 1.75
Comparison between self-reported facial flushing after alcohol consumption and ALDH2 Glu504Lys polymorphism for risk of upper aerodigestive tract cancer in a Japanese population. Cancer Sci (2010) 1.74
Physical activity and colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Sci (2006) 1.72
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol (2011) 1.71
NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell (2012) 1.68
Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev (2010) 1.67
Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol (2007) 1.65
Risk factors for and management of delayed intraperitoneal hemorrhage after pancreatic and biliary surgery. Am J Surg (2007) 1.64